Par Drugs And Chemicals Analyst Review May 2026
- May 27, 2026
- Posted by: Kashish Aggarwal
- Category: News
This Par Drugs And Chemicals analyst review for May 2026 covers all critical data investors need for PARDRUGS at Rs 85. Par Drugs and Chemicals is a pharmaceutical API manufacturer. This Par Drugs And Chemicals analyst review analyses technical levels, business fundamentals, valuation, and key risks for PARDRUGS through FY27.
Click Here – Get Free Investment Predictions
Par Drugs And Chemicals Analyst Review: Company Snapshot May 2026
Par Drugs manufactures generic pharmaceutical APIs and intermediates. The table below summarises key metrics for this Par Drugs And Chemicals analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | PARDRUGS |
| Sector | Pharmaceuticals – APIs |
| CMP (May 2026) | Rs 85 |
| 52 Week High | Rs 125 |
| 52 Week Low | Rs 65 |
| Market Cap | Rs 500 Crore |
| Trailing P/E | 18x |
| Analyst Consensus Target | Rs 106.25 |
| Bull Case Target | Rs 131.75 |
| Bear Case Target | Rs 72.25 |
Analyst Insight: Par Drugs And Chemicals Analyst Review for FY27
Associate Director Kunal Singla suggests watching Par Drugs And Chemicals closely in May 2026. At Rs 85, Kunal Singla flags Pharmaceuticals – APIs sector dynamics as the key driver for PARDRUGS’s price action. Support is near Rs 66.30 and resistance near Rs 90.10. Kunal Singla’s perspective in this Par Drugs And Chemicals analyst review is not a buy recommendation.
Technical Analysis in This Par Drugs And Chemicals Analyst Review
This Par Drugs And Chemicals analyst review places PARDRUGS at Rs 85 within its 52-week band of Rs 65 to Rs 125. The 14-day RSI, MACD signal, and volume profile are key technical inputs when evaluating PARDRUGS.
The Par Drugs And Chemicals analyst review identifies support in the Rs 66.30 to Rs 80.75 range and resistance in the Rs 90.10 to Rs 95.62 zone. A sustained close above Rs 90.10 could signal momentum toward the analyst consensus target of Rs 106.25.
Screen the best stocks on the Univest Screener.
Support and Resistance in This Par Drugs And Chemicals Analyst Review
- Support Zone: Rs 66.30 to Rs 80.75 – this Par Drugs And Chemicals analyst review identifies this as a potential accumulation signal for PARDRUGS.
- Resistance Zone: Rs 90.10 to Rs 95.62 – the Par Drugs And Chemicals analyst review flags a close above Rs 90.10 as a positive signal for PARDRUGS.
- Consensus Target: Rs 106.25 is the base-case target in this Par Drugs And Chemicals analyst review.
Business Segments in This Par Drugs And Chemicals Analyst Review
Pharmaceutical API Manufacturing
This primary segment drives revenue and margin for Par Drugs And Chemicals, supporting the earnings trajectory toward Rs 106.25 in this Par Drugs And Chemicals analyst review.
Generic Drug Intermediates
This segment adds meaningful scale to Par Drugs And Chemicals’s model and is a key EPS contributor through FY27 as identified in this Par Drugs And Chemicals analyst review.
Export APIs
This growth frontier is a potential re-rating catalyst for PARDRUGS and a key element of this Par Drugs And Chemicals analyst review.
Valuation: Par Drugs And Chemicals Analyst Review Bull Bear Base Case
At Rs 85 and P/E of 18x, this Par Drugs And Chemicals analyst review sets three scenarios: bull case Rs 131.75, base case Rs 106.25, and bear case Rs 72.25.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 131.75 | Strong FY27 delivery and Pharmaceuticals – APIs re-rating |
| Base Case | Rs 106.25 | Moderate growth per analyst consensus in this Par Drugs And Chemicals analyst review |
| Bear Case | Rs 72.25 | Earnings miss or macro headwinds for PARDRUGS |
FY27 Outlook in This Par Drugs And Chemicals Analyst Review
This Par Drugs And Chemicals analyst review for FY27 is constructive provided PARDRUGS delivers on earnings expectations. Q1 FY27 results will be the first checkpoint. Investors should monitor Pharmaceuticals – APIs indicators, RBI policy, and FII flow trends.
Key Risks in This Par Drugs And Chemicals Analyst Review
This Par Drugs And Chemicals analyst review identifies four key risks for PARDRUGS: macro slowdown, input cost pressure, FII selling, and Q1 FY27 earnings disappointment.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Par Drugs And Chemicals Analyst Review Verdict May 2026
This Par Drugs And Chemicals analyst review concludes that PARDRUGS at Rs 85 presents a defined risk-reward with consensus target Rs 106.25. The 52-week range of Rs 65 to Rs 125 provides further context. Use this Par Drugs And Chemicals analyst review as a research reference and consult a SEBI-registered advisor before investing in PARDRUGS.
FAQs: Par Drugs And Chemicals Analyst Review 2026
What is the analyst target for Par Drugs And Chemicals in 2026?
The Par Drugs And Chemicals analyst review consensus target is Rs 106.25, bull case Rs 131.75, bear case Rs 72.25.
Is Par Drugs And Chemicals a good buy at Rs 85?
At Rs 85 with PE 18x and target Rs 106.25, this Par Drugs And Chemicals analyst review is constructive for 12-month investors. Consult a SEBI-registered advisor before acting on this Par Drugs And Chemicals analyst review.
What is the 52-week high and low of Par Drugs And Chemicals?
52-week high is Rs 125 and 52-week low is Rs 65. This Par Drugs And Chemicals analyst review contextualises PARDRUGS at Rs 85 within this range.
What are the key risks for Par Drugs And Chemicals?
Key risks in this Par Drugs And Chemicals analyst review: macro slowdown, input cost pressure, FII selling, and competitive pressure in the Pharmaceuticals – APIs sector.
Where can I track live data for Par Drugs And Chemicals?
Track Par Drugs And Chemicals’s live price on the Univest Screener to complement this Par Drugs And Chemicals analyst review with real-time data.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
